ReviewEvidence-based complementary and alternative medicine : eCAM2019
Pharmacological Activities of
Review in Evidence-based complementary and alternative medicine : eCAM, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Botany, traditional uses, phytochemistry, pharmacology, toxicology and processing ofFrontiers in pharmacology · 2025Review
- Natural products for managing metabolic syndrome: a scoping review.Frontiers in pharmacology · 2024Article
- Bioactive Steroids Bearing Oxirane Ring.Biomedicines · 2023Review
- Review
- Potential Therapeutic Implication of Herbal Medicine in Mitochondria-Mediated Oxidative Stress-Related Liver Diseases.Antioxidants (Basel, Switzerland) · 2022Review
- Review
- Article
- Beneficial Activities ofNutrients · 2022Article
- Alismatis Rhizoma methanolic extract-Effects on metabolic syndrome and mechanisms of triterpenoids using a metabolomic and lipidomic approach.Frontiers in pharmacology · 2022Article
- Promising Anticancer Activities ofNutrients · 2021Review
- Alisol A 24-acetate stimulates lipolysis in 3 T3-L1 adipocytes.BMC complementary medicine and therapies · 2021Article
- The Anti-Obesity Effect of Traditional Chinese Medicine on Lipid Metabolism.Frontiers in pharmacology · 2021Review
- Based on Network Pharmacology and RNA Sequencing Techniques to Explore the Molecular Mechanism of Huatan Jiangzhuo Decoction for Treating Hyperlipidemia.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Herbal formulation MIT ameliorates high-fat diet-induced non-alcoholic fatty liver disease.Integrative medicine research · 2020Article
- Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application.Frontiers in pharmacology · 2020Review
- Identify Molecular Mechanisms of Jiangzhi Decoction on Nonalcoholic Fatty Liver Disease by Network Pharmacology Analysis and Experimental Validation.BioMed research international · 2020Article
- Triterpenoids FromFrontiers in chemistry · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a rapidly emerging hepatic manifestation of metabolic syndrome. However, its unrevealed mechanism and complicated comorbidities have led to no specific medication, except for weight loss and lifestyle modification.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.